- Supported exchanges /
- F /
- EAJF.F
VALIRX PLC LS-001 (EAJF F) stock market data APIs
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
VALIRX PLC LS-001 Financial Data Overview
| 0.0155 | |
| 0.0195 | |
| - | |
| 0.0195 | |
| 0.0155 | |
| 0.01-0.146 | |
| 2 588 K | |
| 132 M | |
| 9 600 | |
| 0.589 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
VALIRX PLC LS-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 9 600
- EBITDA -1 966 799
- Earnings Per Share -0.02
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get VALIRX PLC LS-001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get VALIRX PLC LS-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
